SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05), Zacks reports. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The company had revenue of $17.78 million during the quarter, compared to the consensus estimate of $16.76 million. SOPHiA GENETICS updated its FY 2025 guidance to EPS.
SOPHiA GENETICS Trading Down 2.0 %
Shares of SOPHiA GENETICS stock traded down $0.06 during trading on Friday, reaching $2.93. The company's stock had a trading volume of 15,281 shares, compared to its average volume of 62,572. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. SOPHiA GENETICS has a 52-week low of $2.58 and a 52-week high of $6.28. The firm's 50-day moving average is $3.05 and its two-hundred day moving average is $3.34. The company has a market cap of $195.39 million, a price-to-earnings ratio of -2.69 and a beta of 1.03.
Analysts Set New Price Targets
Separately, BTIG Research set a $5.00 price objective on shares of SOPHiA GENETICS in a research report on Thursday, March 6th.
Get Our Latest Analysis on SOPH
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
Featured Stories
Before you consider SOPHiA GENETICS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.
While SOPHiA GENETICS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
